This content is relevant for:Germany / Europe / World
Research and Development / Epidemic Prevention / Healthcare, General
Poverty-related and Neglected Diseases (PRND) affect more than one billion people globally. However, because these diseases predominantly impact the world’s poor, there is limited economic incentive for commercial pharmaceutical companies to invest in developing diagnostics, vaccines, drugs, vector control products, and other new technologies to combat them. Here is where Product Development Partnerships (PDPs) engage. PDPs are non-profit organizations that conduct or facilitate research and development (R&D) of new products1 for people who suffer from diseases and health threats underserved by commercial markets.
The German Federal Ministry of Education and Research (BMBF) has been funding R&D ofproducts and technologies for the prevention, diagnosis, and treatment of PRNDs through PDPs since 2011. Due to the promising results of the PDPs to date and the continued high funding needs in this area as described above, the BMBF will continue the funding in a third phase. This new funding phase is part of the BMBF's "Global Health" funding priority and contributes to the Federal Government’s Global Health Strategy.
BMBF has mandated KfW to support it in preparing and implementing this third funding phase, including this Call for Proposals (CfP) process, and KfW now invites sealed Proposals from eligible institutions for the funding of R&D products.
Please click "Log in" to log in with your user details. If you do not have a GTAI user account yet, you can sign up free of charge in order to have access to all our services and information. Sign up now.